objective To describe the characteristics and management of Diabetes mellitus (DM) patients from low-and middle-income countries (LMIC).
Introduction
Diabetes mellitus (DM) is one of the largest global health emergencies of the 21st century. In 2017, there were 425 million adults estimated to be living with DM, and this number is predicted to increase to 629 million by 2045 [1, 2] . An estimated 80% of people with DM live in low-or middle-income countries (LMICs) [2] . Although studies are few, compared to those on individuals living in highincome countries, DM patients in LMIC may present at a younger age or with more advanced disease and more disease complications [3] . Healthcare access and long-term care may be more problematic, with inadequate access to laboratory testing, medication such as insulin, health information and limited self-management of patients [4] . Also, people living with DM in tropical countries may be at higher risk for infectious diseases [5] . Cardiovascular complications, the leading cause of mortality and morbidity among patients with type 2 DM [6, 7] , may also be more common among people living with DM in LMICs [8] [9] [10] , due to higher rates of smoking, and less access to cardiovascular risk assessment and management [11] [12] [13] [14] [15] . Assessment of diabetes disease characteristics, cardiovascular risk profile and medical management of people living with DM has been undertaken in some country-specific studies [16] [17] [18] and compared across LMIC countries in Asia and subSaharan Africa [12, 19, 20] . Such studies are needed to help improve management of DM and reduce its progression and complications.
As part of the TANDEM project on DM and tuberculosis [21] , we have systematically characterised people with DM in government health clinics or hospitals in Indonesia, Peru, Romania and South Africa, four countries that are witnessing a rapid growth of DM [1] . The TANDEM project has examined the prevalence of tuberculosis among individuals with DM, but this also allowed us to characterise DM patients in these four countries. Thus, the objectives of the present study were to: (i) establish disease phenotype and cardiovascular risk profile of DM patients; (ii) characterise medical treatment, and gaps between national and international guidelines and actual patient care as a 'cascade of care', and (iii) identify possible sociodemographic factors associated with inadequately controlled DM or with suboptimal management.
Methods

Setting and design
This study is part of The Concurrent Tuberculosis and Diabetes Mellitus (TANDEM) study which aims to develop methods for better screening and management of combined tuberculosis and DM, and to increase basic knowledge about the link between the two diseases [21] . TANDEM is a multicentre prospective study with field sites in Peru, Romania, South Africa and Indonesia, countries with diverse healthcare systems and population demographics, but all with a relatively high burden of tuberculosis and an increasing prevalence of DM [1, 22] . The TANDEM study recruited 2096 consecutive patients (December 2013 to June 2016) with previously diagnosed DM to be screened for tuberculosis through symptom screen, chest X-ray and sputum examination. To identify possible factors associated with tuberculosis, all patients were uniformly and systematically characterised in terms of DM disease characteristics and management. These data were used for the current study, excluding those patients in whom active tuberculosis was diagnosed.
In Indonesia, DM patients were recruited in 25 community health centres and from the endocrine clinic in a tertiary public referral hospital in Bandung. In Peru, patients were recruited at a diabetes clinic at one tertiary level public hospital in Lima, as diabetes care in the public domain is mainly provided by hospitals. In Romania, patients with DM were recruited from two secondary level hospitals in Craiova. In South Africa, patients were recruited at three community health centres in the northern Cape Town metropolitan area. For more details of study site selection and location, see Supplementary File.
Study procedures
Patients with known DM (either under care for DM or on DM medication) who were above 18 years of age *Joint first authors. † Member's details of TANDEM Consortium are listed in Appendix S1.
were eligible; those with gestational or steroid-induced diabetes were excluded. Having obtained written informed consent, research doctors conducted an interview, using a validated questionnaire, with each patient asking about their socio-demographic characteristics (age, gender, and education, and assets to link to socioeconomic status), behavioural characteristics such as self-reported smoking status and alcohol consumption, and diabetes characteristics such as DM history, complications, medication and management. Research nurses followed a standard operating procedure for taking patients' blood pressure using a digital device, and for measuring height, weight (using digital scales) and waist measurement for calculation of body mass index (BMI) and central obesity. Venous blood was taken for laboratory glycated haemoglobin (HbA1c), and urine for albumin to creatinine ratio (ACR). All HbA1c samples were analysed in an accredited laboratory with NGSP certification, using the HPLC methods according to WHO guidelines and with DCCT aligned assays. Lipid profile and creatinine, recorded as the most recent test undertaken within the previous month, was obtained from the medical records for a subset of patients. 
Data management and variables used
Demographic and clinical data were entered onto a case report form and then into a secure, centrally managed, electronic database (REDCap). Other data, such as laboratory results, diabetes history, smoking status and complications were entered directly into REDCap. Data quality was checked on a monthly basis for accuracy and completeness.
Blood pressure was categorised according to the JNC VIII [23] 2 ). Central obesity for female patients in all sites was categorised as a waist circumference (WC) of ≥80 cm. Central obesity for males was categorised as a WC ≥90 cm for Indonesia and Peru and ≥94 cm for Romania and South Africa [26] . Laboratory HbA1c was categorised into three groups <7.0; 7.0-9.9; ≥10% (<53; 53-85; ≥86 mmol/mol) for analysis [27] . ACR categories were normal (<30 lg/mg); moderately increased (30-299 lg/mg), and albuminuria (≥300 lg/ mg). Low-density lipoprotein (LDL) was categorised as dyslipidaemia if the result was ≥100 mg/dl (2.6 mmol/l), or if high-density lipoprotein (HDL) was ≤40 mg/dl (1.0 mmol/l) for males or ≤50 mg/dl (≤1.3 mmol/l) for females [27, 28] . Estimated glomerular filtration rate (eGFR) was calculated according to the CKD-EPI creatinine equation 2009 [29] . Principal Component Analysis [30] was performed to build a socio-economic status index based on asset ownership by patients that included nonsellable (possession of a bank account, type of sanitation facility, household water source) and sellable assets (e.g. stove, refrigerator, washing machine, television).
Diabetes mellitus treatment guidelines for the four countries
The gap between optimal and actual treatment with insulin, antihypertensive, lipid-lowering and antiplatelet drugs was calculated using patient's HbA1c, blood pressure, LDL and cardiovascular (coronary artery disease, myocardial infarction, angina) disease history. Among patients using insulin, antihypertensive and lipid-lowering drugs, HbA1c, blood pressure and LDL values were used to examine what proportion of patients reached desired treatment targets according to national guidelines [19, 27, 28, 31, 32] :
• Patients with HbA1c ≥10% (86 mmol/mol) should have insulin added to their medications.
• Patients with blood pressure ≥140 systolic or ≥90 diastolic should be managed with antihypertensive medication.
• Cardiovascular complications should be managed with aspirin.
Macrovascular complications included infarct (coronary artery disease, angina, myocardial infarction), heart failure, cerebrovascular disease, peripheral vascular disease). Microvascular complications included a history of renal disease, neuropathy, eye problems (blindness, impaired vision, glaucoma, cataract).
Statistical analysis
Descriptive data are presented as mean and standard deviation for normally distributed data, median and interquartile range (IQR) for non-normally distributed data, and proportions for categorical data. Odds ratios and 95% confidence intervals were estimated using logistic regression to investigate factors associated with severe disease (defined as an HbA1c ≥10% (86 mmol/mol) or macrovascular or microvascular complications) and poor medical treatment (defined as patients not receiving insulin, antihypertensives or aspirin when it is indicated). We then undertook multiple logistic regression, including all the variables in the model. A test for trend was done for ordinal variables where the trend was consistent but no individual levels were statistically significant. Univariate and multivariate analysis was not undertaken for South Africa due to the small number of participants. All analyses were stratified by site, given the substantial heterogeneity expected. Statistical analyses were performed using STATA Version 12.1.
Results
General patient characteristics
After excluding 28 DM patients with active tuberculosis, 2068 were included in Indonesia (n = 783), Peru (n = 599), Romania (n = 603) and South Africa (n = 83). Baseline characteristics are shown in Table 1 . All patients in Peru and South Africa had type 2 DM, 98% in Indonesia and 87% in Romania. Almost half of the patients (49%) had had DM for at least five years. Their median age was 59 years, 63% were female and 33% had an education of primary school or less.
Glycaemic control and diabetes complications
The median HbA1c across all four sites was 8.7% (IQR 7.0-10.7%) (72; 53-93 mmol/mol). It was highest in South Africa (10.4%; 90 mmol/mol) and appeared lowest in Peru (7.7%; 61 mmol/mol), although HbA1c was missing for a substantial proportion of DM patients in Peru (Table 1 ; Figure S1 ). The proportion of patients using metformin was 63% overall, with the greatest use in South Africa (90%), and the lowest in Indonesia (55%). Insulin, either alone or in combination with oral medication, was used by 38% of patients overall, with the highest use of insulin in Romania (67%) where patients were recruited in hospital wards, and the lowest in Peru (20%) ( Table 1) . Disease complications including heart disease, eyesight problems, micro-and macroalbuminuria, and decreased renal clearance were common across all populations (Table 1) .
Cardiovascular risk profile
On average, patients had a moderately increased cardiovascular risk profile, as shown in Table 2 . Overall, almost half of the DM patients had a BMI categorised as obese (46%). This was highest for the Indonesian cohort when using the Asia Pacific Criteria of BMI (Obese I, 39.3%; Obese II, 14.2%). Eighty-five percent of females and 63% of males across sites were categorised as having central obesity. Uncontrolled hypertension in patients not on antihypertensives, was reported in 36% of the overall cohort and this was highest in South African patients (52%) and lowest in patients in the Peru site (15%). Current smoking was reported in 13% of patients across all sites. In a subset of patients in three sites, dyslipidaemia (LDL ≥100 mg/dl (2.6 mmol/l)), for patients not on statins, was reported in 74% (Indonesia 80%; Romania 55%; South Africa 52%).
Medical treatment
Uptake of treatment and success in terms of reaching treatment targets was suboptimal, with large variation between sites. For instance, of patients with an indication for insulin (HbA1c ≥10%, 86 mmol/mol), 55% were using insulin, varying from 80% in Romania, to 73% in South Africa, 41% in Peru, and 32% in Indonesia (Table 3) . Of patients in these sites who were on insulin, only a small proportion had their HbA1c controlled to <7% (53 mmol/mol) (Table 4 ). Similarly, of 913 patients with hypertension, less than half (47%) were taking antihypertensive drugs (Table 3) , while only 40% of 711 patients taking antihypertensive drugs had their blood pressure controlled (Table 4) . Of 326 patients reporting cardiovascular complications, 30% were on aspirin, ranging from 86% in South Africa to 20% in Indonesia (Table 3 ). Blood lipids were only available for a subset of patients, and not for patients in Peru. Of 267 patients with dyslipidaemia (LDL ≥100 mg/dl (2.6 mmol/l)), 29% were treated with statins (Table 3) . Of 407 patients who were taking statin medication, only 8% had a LDL level of <100 mg/dl (2.6 mmol/l) ( Table 4) .
Factors associated with disease severity and medical treatment
Disease severity and medical treatment and underlying factors differed substantially between countries. We assessed risk factors for disease severity as defined We assessed what factors were associated with noncompliance to treatment guidelines with regard to use of insulin, antihypertensives and aspirin (Tables S4-S6) 
Discussion
Numerous studies have addressed the growing burden of diabetes in low-and middle-income countries but detailed patient data like disease complications and specific drug treatment have mostly been reported in single-site studies. In the context of the TANDEM project on the interaction between diabetes and tuberculosis [21] , we have pooled systematically collected detailed characteristics of more than 2000 DM patients from Indonesia, Peru, Romania and South Africa. Three main conclusions could be drawn. First, both among hospitalised and ambulatory patients in these four countries, glycaemic control is often poor, disease complications are common, and the cardiovascular risk is often high. Second, across different settings many patients who qualify for insulin, antihypertensive, lipidlowering drugs or aspirin do not receive these drugs. Third, of those on these drugs, only a minority reach desired treatment targets. These findings underline the need to identify treatment barriers and secure optimal DM care in low-and middle-income countries where most people with DM live.
Recent studies have addressed the 'cascade of care' for diabetes [19, 20, 33] . For instance, based on population surveys in 12 sub-Saharan African countries it was estimated that only 37% of DM patients were aware of their diagnosis, and only 11% received medication [19] . But these studies have also stressed the lack of data regarding the burden of diabetes-related complications. Systematically collecting data from individual patients, we could precisely characterise disease severity, complications and drug treatment. With regard to disease severity, hyperglycaemia was common yet use of insulin was low. Poor glycaemic control in Romania could be due to a selection bias as only inpatients were investigated, who are more likely to have poor disease management or infections or other disease complications leading to hyperglycaemia. Among ambulatory patients in the other Table 2 Cardiovascular risk profile and medication management of patients according to recruitment site sites, the proportion of patients with an HbA1c <7% (53 mmol/mol) ranged from 11% to 28%. Moreover, from discussion with local practitioners and evaluation of patient records it became clear that HbA1c was not routinely measured, and in Peru even during this study it proved impossible in a large proportion of patients due to the local unavailability of HbA1c tests. Lack of HbA1c monitoring probably contributes to poor glycaemic control. Other factors include insufficient or inadequate use of insulin, which is often not available [34] , too expensive, or difficult to use because of patients unwillingness or inability to do self-monitoring of blood glucose [35] . Even metformin and sulphonylurea derivates, widely used and cheap diabetes drugs, are often not available or prohibitively expensive [36, 37] .
Like poor glycaemic control, disease complications as reported in other studies [7, 9, 38, 39] , were common, with many patients suffering from cardiovascular disease, eyesight problems and renal disease. Local health providers may not be fully aware of disease severity of their patients, because time and resources are often lacking to conduct systematic assessment [14, 40] , as was done in this study. Our study may even underestimate the proportion of patients with disease complications as we mainly relied on patient history and medical records and did not perform electrocardiography, fundoscopy, or other related tests. Our cross-sectional study was unable to establish what proportion of complications were already present at the time of initial presentation, and how often complications develop while patients are under DM care, as a result of insufficient glycaemic control and cardiovascular risk management. It is clear that both earlier detection of DM and better glycaemic control and cardiovascular risk management are needed. Cardiovascular risk profile was elevated in most patients. Obesity, uncontrolled hypertension and dyslipidaemia were common. The proportion of patients smoking was less than we had expected, ranging from 6% in Peru, 14% in Indonesia, 16% in Romania and 37% in South Africa. It is possible that patients may have given socially desirable answers, particularly as a much higher proportion reported having stopped smoking in most sites. Also, in these countries, smoking is more common among men, while almost two-thirds of study patients were female.
We found large discrepancies between guidelines and practice regarding use of insulin and cardiovascular risk management. Approximately, half of those patients qualifying for insulin or antihypertensive drugs received these drugs. Similarly, of those with an indication for statins, or aspirin as secondary prevention of cardiovascular disease, only 30% were prescribed these drugs. And of those who were prescribed these drugs, targets in terms of HbA1c, blood pressure and LDL were only met for 8%, 40% and 8% respectively. This could be due to incomplete treatment adherence, which was not assessed in this study, or insufficient dosing. Optimal glycaemic control with insulin is difficult to achieve without self-monitoring of blood glucose, but this is not routine in government clinics in any of the four sites. Similarly, self-measurement of blood pressure is rarely done, and blood pressure is not measured at each clinic. Limited time and space in clinics, or low awareness or lack of training among health professionals may contribute to the poor 'cascade of care' in DM care in lowresource settings [14, 38, 40, 41] .
This study suffers from limitations. First, as it was a cross-sectional study of patients who had had DM for a median of 5 years or more, we do not know how many patients present with complications, and how many patients die from DM over time or disengage from DM care. Second, it is unlikely that our data are fully representative of the four countries. Assessment of the DM phenotype and treatment was not a primary objective of TANDEM, and patients were only recruited in a limited number of clinics. In Romania, we only included inpatients, who likely suffer from poorer glycaemic control and more disease complications. Third, complications were mostly self-reported. It would have been preferable to have a formal assessment by a cardiologist, neurologist and eye physician but this was beyond the scope of this study. Fourth, for some characteristics there were a lot of missing data. For instance, recent lipid measurements, not included in the TANDEM assessment, but extracted from patient records, were not available in Peru, and only in a minority of patients from the other sites; and HbA1c was often missing in Peru and South Africa most likely due to frequent unavailability of laboratory tests. Lack of coverage from public health insurance or unawareness among health professionals may also be involved.
Despite these limitations, we feel that our study, using a standardised method and addressing the most important disease and treatment characteristics, shows a clear picture of the severity of DM in these countries across four continents and of the unmet needs in terms of drug treatment. Future studies should examine these issues longitudinally, identify barriers to optimal DM care, and evaluate possible interventions to help improve the outcome of DM patients.
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